Drugs / BGB-53038
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06585488 | Dec 2024 → Apr 2026 | colorectal cancer, esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer +3 | BeOne Medicines | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-53038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585488 ↗ |
| Action | Inhibit | “a Pan-KRAS Inhibitor” NCT06585488 ↗ |
| Route | Oral | “Administered orally” NCT06585488 ↗ |
| Target | KRAS | “a Pan-KRAS Inhibitor” NCT06585488 ↗ |